ALLOAllogene Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−38% vs 200-day) and a crowded short (+16% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 24). Price is −38% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ALLO is trading
Allogene Therapeutics, Inc. is +2.5% over the past year while the S&P 500 is +16%: 14 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −38%
vs 200-day average · a clear downtrend
- RSI (14)
- 24
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 59%
Below its 52-week high
Details›
- Last close2026-10-23
- $1.24
- 1 monthS&P 500 −0.94%
- −25%
- 1 yearS&P 500 +16%
- +2.5%
- 5 yearsS&P 500 +86%
- −92%
- vs 50-day average$1.70
- −27%
- 52-week high
- $3.06
- 52-week low
- $1.05
- Annualised volatility
- 92%
| Year | Return |
|---|---|
| 2026 (year to date) | −9.5% |
| 2025 | −36% |
| 2024 | −34% |
| 2023 | −49% |
| 2022 | −58% |
| 2021 | −41% |
| 2020 | −2.8% |
| 2019 | −3.5% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 5 of 8 | +7.7% |
| Feb | 8 | 6 of 8 | +11% |
| Mar | 8 | 1 of 8 | −13% |
| Apr | 8 | 4 of 8 | +0.69% |
| May | 8 | 2 of 8 | −1.1% |
| Jun | 8 | 3 of 8 | +2.1% |
| Jul | 8 | 4 of 8 | +3.0% |
| Aug | 8 | 3 of 8 | −4.3% |
| Sep | 8 | 5 of 8 | −3.7% |
| Oct | 8 | 1 of 8 | −11% |
| Nov | 8 | 3 of 8 | +2.6% |
| Dec | 8 | 1 of 8 | −10.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.